Latest Developments in the Healthcare Sector: Complementary Research on Parnell Pharmaceuticals, Medovex, Cipher Pharmaceuticals, Histogenics, Bio Blast Pharma

May 18, 2015, 08:20 ET from Analysts Review

NEW YORK, May 18, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Parnell Pharmaceuticals Holdings Ltd. (NASDAQ: PARN), Medovex Corp. (NASDAQ: MDVX), Cipher Pharmaceuticals Inc. (NASDAQ: CPHR), Histogenics Corporation (NASDAQ: HSGX), and Bio Blast Pharma Ltd. (NASDAQ: ORPN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.


Today's update concerns the following companies:


Full PDF Download Links (you may have to copy and paste the following links into your browser):

PARN Research Report: ( ),

MDVX Research Report: ( ),

CPHR Research Report: ( ),

HSGX Research Report: ( ),

ORPN Research Report: ( ).



Analyst Update: Financial Results, Partnership, and Drug Approval

U.S. stocks mostly drifted between modest gains and losses on Friday, May 15, 2015 as investors remained cautious over weaker than expected economic data. The Dow Jones Industrial Average gained 0.11%, to finish at 18,272.56, the S&P 500 rose 0.08%, to 2,122.73, and the NASDAQ Composite ended the day at 5,048.29, down 0.05%. European stocks closed lower on Friday amid rise in the value of euro against dollar. Germany's DAX 30 lost 0.98%, France's CAC 40 fell 0.71%, and London's FTSE 100 closed 0.18% lower on Friday. Meanwhile, Asian markets painted a mixed picture on Friday. The Shanghai Composite fell as expectation of Chinese stimulus measures cooled, while Hong Kong's Hang Seng and Japan's Nikkei gained on Friday.

Parnell Pharmaceuticals, on April 22, 2015 reported its business results for the first quarter 2015. Revenue for Q1 2015 was AUD$1.5 million, an increase of 6.2% from a year ago. The Company reported a net income of AD$0.1 million, or earnings per share of AD$0.004 for Q1 2015, compared to a net loss of AD$6.4 million, or earnings per share of AD$0.78, for Q1 2014.

On May 7, 2015 Medovex Corp., announced that it has entered into an exclusive U.S. marketing agreement with Hill-Rom, a leading provider of medical technologies and related services for the health care industry around the world. The agreement covers the exclusive marketing of Medovex's Streamline IV Suspense System IV, or ISS™.

Cipher Pharmaceuticals (Cipher), on May 13, 2015, announced financial and operational Results for Q1 2015. Total revenue for Q1 2015 was $9.2 million, up 17% YoY, primarily due to strong performance of its isotretinoin products.

Histogenics Corporation announced its financial results for Q1 2015 on May 14, 2015. The Company reported a net loss of $8.0 million, or $0.60 per share for Q1 2015, compared to a net loss of $3.4 million, or $5.90 per share for the same period in 2014.

BioBlast Pharma, on April 22, 2015, announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Cabaletta for the treatment of patients with Oculopharyngeal Muscular Dystrophy (OPMD).


About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.


Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit:

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review